Ozempic Face: Why Semaglutide Causes Facial Volume Loss

What Is "Ozempic Face"?

"Ozempic face" is a term coined by clinicians and the media, not a diagnosis and not an entry in any drug label. It describes the visible facial aging that some people notice during significant weight loss on a GLP-1 medication. The common signs are sunken or hollowed cheeks, more prominent nasolabial folds (the creases that run from the nose to the corners of the mouth), thinning around the eyes, and a generally gaunt or drawn appearance. Because the underlying cause is weight loss rather than the drug itself, the same look can follow any rapid weight loss, whether from dieting, illness, or surgery.

A peer-reviewed case series (Catalfamo et al., Journal of Clinical Medicine, 2025) gave clinicians a working description: a prematurely aged and fatigued facial appearance driven by rapid weight loss and the loss of subcutaneous facial fat. That phrasing helps practitioners talk about it consistently, but it does not make Ozempic face an official labeled side effect of semaglutide.

Why "Ozempic Face" and Not "Wegovy Face"?

Both brands contain the same active ingredient, semaglutide. Ozempic is the type 2 diabetes brand, and Wegovy is the obesity brand, but the molecule is identical. "Ozempic face" entered everyday vocabulary first because Ozempic was widely used off-label for weight loss before Wegovy was approved for that purpose. The mechanism is the same for either brand, so everything in this article applies equally to both. For a closer look at how the two compare, see our Ozempic vs Wegovy guide.

Why Does Semaglutide Cause Facial Volume Loss?

The short version: semaglutide is very effective at producing weight loss, and the face loses fat along with the rest of the body. There is no special facial mechanism. To see why the change can look so dramatic, it helps to understand how facial fat is arranged and what the limited research has measured.

The Biology of Facial Fat

The face holds fat in two layers. The superficial fat pads sit just under the skin and provide the soft, full contour associated with a youthful look. The deep fat pads sit closer to bone and muscle, beneath the SMAS layer, and act as structural support. Both are facial fat compartments, and both shrink as we age, which is a major reason faces look more hollow over the decades. When body fat falls quickly from any cause, including caloric restriction or a GLP-1 medication, these facial pads shrink in proportion. The skin that used to drape over a fuller cushion now has less to support it.

The superficial and deep facial fat pads shrink in proportion as body fat falls, flattening the midface contour.

What the Research Shows

The first peer-reviewed measurement of this effect came from Sharma and colleagues (Otolaryngology, Head and Neck Surgery, 2025). The team reviewed head and neck imaging taken before and after GLP-1 therapy in 20 patients, median age 54, in a retrospective single-center cohort. Across that group, total midfacial volume fell by a median of about 9 percent. The middle half of patients fell between roughly 3 and 14 percent (the interquartile range), with meaningful numbers landing above and below that band, so the real spread from person to person was wider still. The superficial fat pads lost more (around 11 percent at the median) than the deeper pads (around 7 percent at the median, with the deep-pad interquartile range running even into slightly negative territory for some patients), which fits the visible pattern of cheeks flattening first.

The study also found that facial volume loss tracked with total weight lost: a linear estimate of about 7 percent facial volume for every 10 kilograms of body weight shed. With only 20 patients at a single center, these are directional figures rather than population benchmarks, and the wide individual range is the point worth remembering, not the single median.

For context, semaglutide produced an average 14.9 percent body weight loss at 68 weeks on the 2.4 mg dose in the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021). For someone starting near 85 to 100 kilograms, that is roughly 10 to 15 kilograms lost, which the Sharma estimate would translate to somewhere around 7 to 10 percent midfacial volume loss, consistent with the range that study reported. The fat the body sheds during a caloric deficit comes from across the body, including the face, not from one single compartment in a fixed ratio.

Facial volume loss rose with total weight lost in the Sharma 2025 cohort (N=20), at roughly 7 percent per 10 kg. The spread between patients was wide.

Who Is Most at Risk for Ozempic Face?

Not everyone who loses weight on semaglutide sees a noticeable change in their face. Several factors appear to raise the odds, though the uncertainty is real: no large prospective trial has quantified these risk factors specifically for facial outcomes. They are mechanistically reasonable rather than proven thresholds.

• Older age: Skin elasticity and baseline fat-pad volume both decline with age. When there is less skin recoil and less padding to begin with, the same volume loss reads as more dramatic.
• Faster rate of weight loss: A quicker drop gives skin and soft tissue less time to adapt to the smaller underlying structure.
• Larger total weight lost: Because facial volume loss tracks with total kilograms shed, people who lose a larger absolute amount tend to see more pronounced facial change.
• Facial fat distribution: Some people naturally carry proportionally more fat in the facial compartments. Those who lose it rapidly may notice more difference than someone who stored less there to start with.

Is Ozempic Face Reversible?

This is the question most people ask, and the honest answer has two parts: the volume often comes back, but the skin does not always. If weight is regained, the facial fat pads tend to refill in proportion, and fullness usually returns. Weight regain after stopping a GLP-1 medication is common and well documented: in the STEP 4 trial (Rubino et al., JAMA 2021), participants who switched from semaglutide to placebo regained much of the weight they had lost, while those who stayed on the drug kept losing. So many people who discontinue and regain weight find their facial fullness restores along with it.

The exception is skin laxity. After a large or rapid weight loss, skin that was stretched may not fully retract, especially in older people or after a very large total loss. That loose-skin component can persist even when the underlying fat returns.

Cosmetic options do exist for people bothered by the change, and demand for them has climbed alongside GLP-1 use. A 2026 survey of 406 clinicians (Fabi et al., Dermatologic Surgery) reported a marked rise in requests for facial volume restoration, especially dermal fillers, among patients who had lost weight on GLP-1 medications. Dermal fillers can temporarily restore volume, fat grafting can rebuild it more durably, and radiofrequency-based skin tightening is being studied for laxity. One case series (Catalfamo et al. 2025, 24 patients) reported high patient satisfaction with a subdermal radiofrequency approach at 12 months. These are decisions between a patient and a qualified provider, not a substitute for medical advice, and this article does not recommend any specific procedure.

Can You Reduce the Risk of Ozempic Face?

There is no proven way to prevent facial volume loss entirely while still losing meaningful weight, and no controlled trial has tested these strategies specifically against facial outcomes. What follows are general weight-management practices that are physiologically reasonable and may limit the degree of change. Treat them as "may help," not guarantees.

• A slower, steadier rate of weight loss: Semaglutide's standard titration is already conservative, stepping up roughly every 4 weeks from 0.25 mg to 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg in the STEP 1 protocol. Staying patient through that schedule, rather than rushing, may give tissue more time to adapt.
• Adequate protein intake: Protein supports the preservation of lean mass during a caloric deficit. It will not stop fat loss, but a better body-composition outcome is generally desirable.
• Resistance training: Strength work is associated with preserving lean mass while losing fat, which is sensible for anyone in a sustained deficit.
• Sun protection and skin care: These do nothing about fat loss, but supporting skin quality and resilience is reasonable while the underlying structure changes.

Does This Happen With Other GLP-1 Drugs?

Yes. Facial volume loss is driven by weight loss, not by one specific molecule, so it can follow any treatment that produces substantial weight reduction. Tirzepatide (sold as Mounjaro and Zepbound) is a different compound from semaglutide, but it also produces significant weight loss and can lead to the same facial changes. The Sharma 2025 study described its population as patients on GLP-1 agonists broadly rather than semaglutide alone, and a 2025 systematic review (Daneshgaran et al.) specifically named Ozempic, Wegovy, Mounjaro, and Zepbound when discussing the phenomenon.

Facial change is one of several appearance-related effects people discuss with GLP-1 therapy. Hair shedding is another, covered in our guide on whether semaglutide causes hair loss. For the broader list of what to expect, see the semaglutide side effects guide.